Ranked #8,186 of 8,699 institutional investors
Versant Venture Management, LLC
San Francisco, CA
$88.6M
US stock portfolio at live prices · today −$1.6M (−1.82%)
Market closed. Prices as of Nov 20, 9:11 AM ET
- Value at quarter end (Q3 2026)
- $109M
- Change from Q2 2026
- −$53.5M (−32.91%)
- Positions
- 6 · 0 new, 0 sold out
- Filed
- Nov 13, 2026
Not counted in the ranking: none$8.5M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesGLUE 32.0%IPSC 18.1%JBIO 16.9%CTNM 13.2%LENZ 10.0%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics, Inc. | 3,180,780 | $28.3M | 32.0% | Unchanged |
| IPSC Century Therapeutics, Inc. | 12,166,109 | $16.1M | 18.1% | Unchanged |
| JBIO Jade Biosciences, Inc. | 991,783 | $14.9M | 16.9% | Unchanged |
| CTNM Contineum Therapeutics, Inc. | 1,292,628 | $11.7M | 13.2% | Added +138% |
| LENZ LENZ Therapeutics, Inc. | 2,656,888 | $8.9M | 10.0% | Unchanged |
| SKYE Skye Bioscience, Inc. | 250,962 | $198K | 0.22% | Unchanged |